junB mice developed a myeloproliferative disease with numbers in the peripheral blood were 3-fold increased at 3-4 months of age and reached a 10-fold increase by complete penetrance by 11 months of age (Figure 1 ). Upon necropsy, 7-to 11-month-old diseased junB Ϫ/Ϫ Ubi-6-11 months (Table 1) . Differential blood counts indicated elevated numbers of mature neutrophilic granulocytes junB mice consistently showed a massive enlargement of spleen, lymph nodes, and liver ( Figures 1A-1C ). Histo-( Figure 1D ), but comparable numbers of eosinophilic granulocytes, erythrocytes, and monocytes. Furthermore, imlogical and cytological examination of these organs revealed increased cellularity and a pronounced infiltramunohistochemistry for the macrophage marker F4/80 also indicated similar numbers of tissue macrophages tion by cells positively stained for the myeloid marker chloroacetate esterase (CAE; Figure 1C ). The leukocyte (data not shown). In contrast, none of the wild-type or junB ϩ/ϩ Ubi-junB junB Ϫ/Ϫ Ubi-junB (n ϭ 5) (n ϭ 7) (n ϭ 11) (n ϭ 8) (n ϭ 10) (n ϭ (Figures 1E-1G ). Conversely, a relative decrease in the numbers of B and T cells was observed of Gr-1 hi /Mac-1 hi granulocytes in the spleen and bone marrow, and prominent myeloid hyperplasia in the in mutant spleen and bone marrow, although the total numbers of lymphocytes appeared comparable to conspleen. Interestingly, the onset of the disease was dependent on the age of the junB Ϫ/Ϫ Ubi-junB donor cells. trol when corrected for the increased cellularity. Furthermore, analysis of mutant thymi indicated similar numMyeloid hyperplasia occurred 2 months after reconstitution with cells from 12-month-old donors, but required bers of single and double positive CD4 and CD8 T lymphocytes ( Figure 1F ). Together, these results indi-6 to 9 months with cells from 6-to 7-month-old donors and on average 12 months with cells from 1-monthcate that junB Ϫ/Ϫ Ubi-junB mice develop a progressive myeloid hyperplasia with overproduction of mature neuold donors. Secondary transplantation of mutant bone marrow cells also resulted in a myeloproliferative distrophilic granulocytes.
Furthermore, in 3 out of 19 junB Ϫ/Ϫ Ubi-junB mice ease within 2-5 months after reconstitution (data not shown). In contrast, none of the recipients reconstituted (16%), histological analysis revealed a massive blast cell infiltration of nonhematopoietic organs such as lung, with control bone marrow cells showed any evidence of increased myelopoiesis for up to 15 months after heart, and kidney ( Figure 1H ). Since CAE staining and myeloperoxidase (MPO) immunohistochemistry only transplantation. These results therefore demonstrate that the myeloproliferative disease in junB Ϫ/Ϫ Ubi-junB showed focal areas of positivity in 1 out of 3 blastinfiltrated kidneys, the majority of the blast cells apmice is fully transplantable. peared undifferentiated. These results indicate that the myeloproliferative disease in junB Ϫ/Ϫ Ubi-junB mice can Loss of Ubi-junB Transgene Expression in junB Ϫ/Ϫ Ubi-junB Myeloid Cells progress to blast crisis, thereby recapitulating the natural course of human chronic myeloid leukemia (CML).
To investigate the correlation between JunB levels and the myeloproliferative disease, expression of the endogenous junB gene and the Ubi-junB transgene was anaThe Increased Myelopoiesis in junB Ϫ/Ϫ Ubi-junB Mice Is Cell Autonomous lyzed by RT-PCR and Western blot in different hematopoietic compartments of 9-month-old control and To test whether the myeloproliferative disease is cellautonomous, lethally irradiated wild-type mice were rediseased junB Ϫ/Ϫ Ubi-junB mice (Figure 2 ). In wild-type Figure 2C ). However, a massive reduction or complete loss of Ubi-junB transgene expression was observed in all diseased junB Ϫ/Ϫ Ubi-junB mice investigated between 4 and 12 months of age (n ϭ 9). In contrast, the transgene was stably expressed in purified B lymphocytes from all tested mice. Southern blot analysis of DNA extracted from granulocytes of junB Ϫ/Ϫ Ubi-junB mice lacking transgene expression did not reveal major changes in the integration site nor in the copy number of the transgene ( Figure 2D ). These results indicate that the development of the myeloproliferative disease coincides with an age-dependent and myeloid-specific silencing of the Ubi-junB transgene. Figures 3E and 3F) . liver cells. 
The Absence of junB Expression in ES Cells

Granulocyte Progenitors
To study the cellular mechanisms accounting for the Next, the numbers of granulocyte progenitors in the bone marrow and spleen of junB Ϫ/Ϫ Ubi-junB mice were expansion of the granulocytic compartment, mutant and control splenocytes were cultured in methylcellulosequantified in vitro using colony-forming assays ( Figure  4B) . A less than 2-fold increase in the number of bone based media containing only a single growth factor or cytokine ( Figure 4D ). After 7 days, increased GM-CFU marrow-derived granulocyte/macrophage colony-forming units (GM-CFU) was observed in cultures of 4-to numbers were observed in junB Ϫ/Ϫ Ubi-junB cultures for all the single factors tested, e.g., IL-3, SCF, GM-CSF, 6-month-old junB Ϫ/Ϫ Ubi-junB mice and comparable and G-CSF. Interestingly, the number of cells per colony increased only in cultures containing GM-CSF alone or in combination with the other factors. Next, splenocytes were grown in liquid culture for 72 hr and pulsed for 2 hr with 3 H-thymidine to determine the proliferation rates ( Figure 4E ). When grown with IL-3, SCF, or G-CSF alone, no significant differences were found between the proliferation rates of control and mutant cells. In contrast, junB Ϫ/Ϫ Ubi-junB cells showed dramatically increased proliferation when grown in the presence of GM-CSF, alone or in combination with the other factors. Furthermore, junB Ϫ/Ϫ Ubi-junB splenocytes displayed a faster and stronger dose-dependent proliferative response in response to increasing amounts of GM-CSF, an effect that was completely abolished by cotreatment with a GM-CSF neutralizing antibody ( Figure 4F) . Finally, the fraction of apoptotic granulocytes was determined using double Gr-1/AnnexinV staining ( Figure 4E) . Interestingly, primary junB Ϫ/Ϫ Ubi-junB splenocytes already displayed reduced numbers of Gr-1 hi /AnnexinV hi apoptotic granulocytes compared to control cells. After 72 hr of culture, a 30% to 50% reduction in the numbers of apoptotic granulocytes was observed independently of the cytokine or growth factor used. Mutant bone marrow cells showed similar results in all three assays (e.g, GM-CFU, proliferation, and apoptosis; data not shown). These results indicate that JunB-deficient granulocyte progenitors have increased responsiveness to GM-CSF-mediated proliferation and extended survival. , no expresdemonstrate that JunB is a critical determinant for myelopoiesis since its absence results in a myeloid leukemia. sion of Fc⑀R; data not shown). The JunB-deficient mast cells also displayed reduced expression levels of p16
Altered Gene Expression in
The mechanisms responsible for the loss of junB expression in junB Ϫ/Ϫ Ubi-junB mice remain largely unand increased expression levels of c-jun and Bcl2 (Figure 6B) . Retroviral introduction of JunB into JunB-defiknown, although no major rearrangements or deletions of the Ubi-junB transgene can be detected at the DNA cient mast cells suppressed proliferation by inducing differentiation into mature mast cells (c-Kit lo , Sca-1 lo , level in cells from the myeloid lineage. Interestingly, the Ubi-junB silencing also occurs in wild-type Ubi-junB Fc⑀R lo-hi ) without changing the apoptotic levels ( Figure  6C ). In contrast, ectopic expression of p16 did not intransgenic mice and appears to be independent of the integration site since it is present in junB Ϫ/Ϫ Ubi-junB duce differentiation but led to increased cell death and reduced proliferation. These results indicate that exmice obtained with a second Ubi-junB founder line (data not shown). We are currently investigating whether the pression of JunB is sufficient to fully reverse the prolifer-transcriptional silencing of the human ubiquitin C promoter could be due to cell-type specific epigenetic modifications, such as deacetylation or DNA methylation.
Our results demonstrate that JunB functions during myelopoiesis are to control the numbers of granulocyte progenitors without interfering with granulocyte maturation. It is also important to note that the absence of JunB does not change the numbers of monocytes and macrophages in vivo although JunB-deficient granulocytes display elevated levels of the M-CSF receptor and show increased proliferation in response to recombinant M-CSF in vitro (data not shown). Therefore, JunB seems to be selectively required during late stages of granulopoiesis, most likely after the divergence from the monocytic pathway. JunB is present in mature granulocytes (Lord et al., 1993) , but nothing is known about its expression during the different stages of myeloid differentiation. Furthermore, JunB expression is modulated by var- with bone marrow cells infected with a retrovirus expressing granulocyte-macrophage colony stimulating factor. EMBO J. 8, 441-448.
